Acknowledgement

This activity is provided by Talem Health and ACCESS Oncology.


This activity is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Credit Available

• Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

Target Audience

This activity is designed specifically for oncology nurses, nurse practitioners, and other nursing professionals who provide cancer care in community and non-academic settings. 

Program Overview

Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancer cases, with a 5-year relative survival rate of approximately 7% among patients with advanced or metastatic disease. Although advances in therapy have led to substantial improvements in overall survival, declines in mortality have been less pronounced in rural versus urban areas. Fortunately, oncology nurses play a key role in improving management in these populations, particularly in community-based settings where patients face oncology workforce shortages and long travel distances to larger cancer facilities. In this on-demand CE activity, expert faculty will discuss the latest treatment approaches for advanced NSCLC and important nursing considerations for care. The program will also highlight monitoring and management strategies for treatment-related adverse events and approaches to enhance education and communication with patients.

The content for this enduring activity was recorded during a live webinar on March 28, 2026.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Evaluate the efficacy and safety of the latest treatment approaches for patients with advanced NSCLC in the first- and second-line treatment setting
• Implement evidence-based monitoring and management strategies for treatment-related adverse events associated with immunotherapies, targeted therapies, and antibody-drug conjugates for NSCLC
• Use patient-centered strategies to improve education and communication with patients with advanced NSCLC

Faculty

Marianne J. Davies, DNP, ACNP, AOCNP, FAAN 
Program Manager, Care Signature Oncology Service Line 
Oncology Nurse Practitioner
Yale New Haven Hospital and Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, CT

Lance F. Ortega, MBA, BSN, RN, OCN 
Executive Director, Clinical Operations  
Texas Oncology 
Dallas-Fort Worth, TX 

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


 

Credit Designation Statement

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity: 

Faculty

Marianne J. Davies, DNP, ACNP, AOCNP, FAAN, has no relevant financial relationships to disclose.
 
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationships to disclose. 

Planners, Managers, and Reviewer 
The Talem Health planners, managers, and reviewer have nothing to disclose. 

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CE credit, participants must: 

1. Read the CE information, including learning objectives and disclosure statements. 
2. Complete the pre-test. 
3. View the online activity. 
4. Complete the post-test and evaluation form. 

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download. 

Course Viewing Requirements 

Supported Browsers: 
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets: 
All devices

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

©ACCESS Oncology, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited. 

Media 

Internet activity 

Fee Information 

There is no fee for this educational activity. 

Contact Information 

For questions about this activity, please contact ACCESS Oncology (a division of Talem Health) at 800-913-9370 or cme@talemcme.com.